title: Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis.
abstract: OBJECTIVE
  Ulcerative colitis (UC) is a complex and progressive disease that has a significant humanistic and economic impact in patients and the wider society. Disease control is still an unmet need for a large proportion of patients. The aim of this article was to review the current evidence to assess the feasibility, value, and impact of integrating continuous clinical response (CCR) as a patient-reported outcome into routine management of UC.
  
  
  METHODS
  Literature searches in PubMed, Google Scholar, and conference proceedings were undertaken to retrieve the relevant articles regarding burden and course of disease, outcome measures in UC, tools for measuring disease activity, and models for patient's self-monitoring.
  
  
  RESULTS
  The concept of CCR was first introduced during the PURSUIT-M trial, where evidence was provided to support the clinical and quality of life benefits of achieving CCR. However, patient monitoring as implemented during the trial was not feasible for its use in the real world. Thus, a simple self-reported score (eg, PRO2) to monitor CCR, with good correlation with more complex procedure-driven indices, was identified for its use in routine patient care. Feasibility of introducing this easy-to-use tool over time as an integral part of patient management was also explored.
  
  
  CONCLUSIONS
  The introduction of CCR as a management goal for UC patients may pose the step change needed to improve disease course and patient's life. Providing patients with simple tools to continuously monitor their disease activity is the first step for an integrated self-monitoring model of care in UC.
authors.affiliation: Department of Gastroenterology, Université de Lorraine, Vandœuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
authors.forename: Laurent
authors.initials: L
authors.lastname: Peyrin-Biroulet
authors.affiliation: Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
authors.forename: Gert
authors.initials: G
authors.lastname: Van Assche
authors.affiliation: IBD Unit, Complesso Integrato Columbus, Gemelli Hospital Catholic University Foundation, Rome, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Armuzzi
authors.affiliation: IMS Health, Real-World Evidence Solutions, Barcelona, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Garcia-Alvarez
authors.affiliation: IMS Health, Real-World Evidence Solutions, Barcelona, Spain.
authors.forename: Nuria
authors.initials: N
authors.lastname: Lara
authors.affiliation: Center for Observational and Real-World Evidence (CORE), Merck and Co, Inc, Kenilworth, New Jersey.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Black
authors.affiliation: Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Khalifa
authors.affiliation: Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
authors.forename: Freddy
authors.initials: F
authors.lastname: Cornillie
authors.affiliation: Center for Observational and Real-World Evidence (CORE), Merck and Co, Inc, Kenilworth, New Jersey.
authors.forename: Sumesh
authors.initials: S
authors.lastname: Kachroo
mesh_terms: D003093:Colitis, Ulcerative / Q000628:therapy*; D019468:Disease Management; D006801:Humans; D017060:Patient Satisfaction; D016896:Treatment Outcome
keywords: Disease Activity; Golimumab; PURSUIT; Self-monitoring